2. Management Team
Dan Poscover, MBA Chairman & CEO
Third Rock Ventures, Scientia Advisors, Glenveigh
Pharma, CombinatoRx
Paul Trevithick Chief Technology Officer
Azigo, Bitstream,Inc., Pageflex, Lightspeed
Computers
Thomas Vasicek, PhD VP, Clinical Genetics
Ventana/Roche, Medtronic, Lynx/Solexa, Corning,
Millennium
Joe Dugan, MBA Chief Business Officer
CapGemini, eChain Technology, Knighbridge
Technology, Oracle
David Neafus, MBA, Chief Financial Officer
CPA Alnylam. Infinity, GlycoFi, Millennium, Triton
Resources
Seema Pandya, MBA VP of Marketing
Sanofi, Genzyme, Boston Scientific
Irina Agoulnik, PhD Sr. Director, Operations
Brigham and Women’s Hospital, Dana-Farber
Cancer Institute, Millennium
Confidential 3/20/2013
3. Advisors
Frederick Frank Special Advisor
Chairman – Burrill Securities, Lehman Brothers
Jeffrey Kindler Advisor
Former Chairman & CEO - Pfizer, McDonalds,
General Electric Co.
Dan Bradbury Advisor
Former CEO – Amylin, Board Member - Illumina
Franklyn Prendergast Advisor
Board Member - Eli Lilly & Company, Mayo Clinic
Center for Individualized Medicine, NIH
Paul Billings Advisor
CMO - Life Technologies, National Institute of
Health (NIH), Ancestry.com
Larry Lesko Scientific Advisor
Professor - University of Florida, FDA
Paul Bleicher Scientific Advisor
CMO – Humedica, Phase Forward, Parexel
Confidential 3/20/2013
4. 4
Future of Healthcare: This Drug is For You
One drug for everyone… Precision Medicine
VS
…but, not everyone responds
Right drug for the right patient
Confidential 3/20/2013
5. 5
PanGenX Platform
The right drug to the
Big Data Inputs Applied Genetics
right patient
Ethnicity
Genetics
Ethnicity
Drugs
Cloud-based software platform
Outcomes to predict drug outcomes based
on genetics and ethnicity
Confidential 3/20/2013
9. 9
Drug Development Is Costly
Too few patients respond positively to the drug
WHY? Too many patients suffer side effects
Source: Discoveries Magazine
Confidential 3/20/2013
16. 16
Competitive Advantage
Why PanGenX? Why Now?
• Proprietary, cloud based, SaaS • Plummeting costs of genome
solution integrating semantic sequencing
web technology with applied • Genome data are exploding
genetics
• Pharma’s blockbuster drug
• First-mover & deep knowledge
model no longer works
advantage in diabetes
• FDA pressing pharma for
• High customer switching costs
more targeted therapies
• Scalable through partnerships
into additional therapeutic areas
& healthcare verticals
Confidential 3/20/2013
Editor's Notes
Today same drugs for everyone – enter precision medicine
